RBC Capital lowered the firm’s price target on Corbus Pharmaceuticals (CRBP) to $58 from $65 but keeps an Outperform rating on the shares after its Q1 earnings miss. Bridging data from the company’s Western cohorts with ‘701 and prior clinical data from partner CSPC in China suggests the Nectin-4 ADC could have best-in-class properties, and RBC believes that more clinical data later this year could better de-risk what it sees as a $1B out-year U.S. sales opportunity, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRBP:
- Corbus Pharmaceuticals price target lowered to $56 from $60 at Oppenheimer
- Corbus Pharmaceuticals price target lowered to $40 from $50 at H.C. Wainwright
- Corbus Pharmaceuticals Advances Clinical Pipeline Amid Q1 Loss
- Corbus Pharmaceuticals Receives FDA Fast Track Designation
- Corbus Pharmaceuticals reports Q1 EPS ($1.39), consensus ($1.07)